The Drug Discovery and Medical Technology platforms aim to deliver innovative drugs and medical
technologies to patients with unmet medical needs and/or possessing rare disease currently, we
are conducting research and development with the highest priority given to the order of the
themes and projects shown in the table below.
- The stages are divided into three components, S (seed) stage, L (lead) stage, and P
(clinical) stage, where each stage is further subdivided into S0 to S3, L1 to– L3, and P0 to
P3.
- Project (L3 to P3): Advance candidate compounds, antibodies, or technology to non-clinical
and clinical development under the direction of a project leader.
- Theme (S0 to L2): Promote selection of drug candidates or antibodies, and develop or improve
technology in cooperation with theme leaders and portfolio managers.
- The abbreviations for modality are:
AB: Antibody; BT: Basic Technology; CT/RM: Cell
Therapy or Regenerative Medicine; MD: Medical Device; NA: Nucleic Acid; SM: Small Molecule.
Table1 Oncology area
Theme/Project |
Theme/Project Leader |
Modality |
Project (L3 to P3)/ Theme (S0 to L2) |
Artificial adjuvant vector cells I (WT1) |
FUJII Shin-ichiro |
CT/RM |
Project |
Cancer treatment by iPS NKT Cell |
KOSEKI Haruhiko |
CT/RM |
Project |
Development of tankyrase inhibitors |
SEIMIYA Hiroyuk |
SM |
Project |
Artificial adjuvant vector cells II (HPV) |
FUJII Shin-ichiro |
CT/RM |
Project |
Anti-cancer drugs targeting SIRT2 |
ITO Akihiro |
SM |
Theme |
Unfolded protein response for the development of new
anti-cancer drugs |
MORI Kazutoshi |
SM |
Theme |
Development of anti-cancer drug targeting histone
acetyltransferase |
YUSA Kosuke HARADA Hironori |
SM |
Theme |
Diagnostic and therapeutic molecules on the basis of acrolein as cancer biomarker |
TANAKA Katsunori |
SM |
Theme |
Cell recognition platform by glycan patterns |
TANAKA Katsunori |
BT |
Theme |
Table2 Infectious disease area
Theme/Project |
Theme/Project Leader |
Modality |
Project (L3 to P3)/ Theme (S0 to L2) |
Artificial adjuvant vector cells III (SARS-CoV-2) |
FUJII Shin-ichiro |
CT/RM |
Project |
Antifungal drug |
YOSHIDA Minoru |
SM |
Theme |
Antibody drug development to prevent SARS-CoV-2 infection
|
SAITO Takashi |
AB |
Theme |
Table3 Psychiatric /
neurological disease area
Theme/Project |
Theme/Project Leader |
Modality |
Project (L3 to P3)/ Theme (S0 to L2) |
Development of novel therapeutic agents for mood
disorders targeting mitochondrial permeability transition pore (mPTP) |
KUBOTA-SAKASHITA Mie |
SM |
Theme |
Development of drug for Alzheimer's disease targeting a
new mechanism |
ASO Teijiro |
SM |
Theme |
Development of integrated stress response inhibitors |
ITO Takuhiro |
SM |
Theme |
Pathophysiological investigations and development of molecularly targeted drugs for cerebral aneurysms based on genetic mutations |
NAKATOMI Hirofumi |
SM |
Theme |
Development of drug for repeat diseases |
INOUE Haruhisa |
NA |
Theme |
Development of diagnostic agents for repeat disease |
TANAKA Motomasa |
AB |
Theme |
Development of antibody therapy for Alzheimer’s disease |
TANAKA Motomasa |
AB |
Theme |
Development of GPCR-targeted therapeutics for neurodegenerative diseases |
KAMIGUCHI Hiroyuki |
SM |
Theme |
Table4 Congenital disease area
Theme/Project |
Theme/Project Leader |
Modality |
Project (L3 to P3)/ Theme (S0 to L2) |
Development of G9a inhibitors for treatment of globinopathy (SCD) |
ITO Akihiro |
SM |
Project |
Development of a drug for Fabry disease targeting a
suppression of globotriaosylceramide (Gb3) accumulation |
KOBAYASHI Hiroki |
SM |
Theme |
Drug for congenital aplastic anemia |
HIROYAMA Takashi |
SM |
Theme |
Drug for Diamond-Blackfan anemia |
HIROYAMA Takashi |
SM |
Theme |
Development of drugs for improving mitochondrial
respiratory function |
KOBAYASHI Hiroki |
SM |
Theme |
Discovery of FBS2 inhibitors as novel therapeutics for NGLY1 deficiency |
SUZUKI Tadashi |
SM |
Theme |
Development of anti-cancer drugs using iPS cells derived from VHL patients |
HAYASHI Yohei |
SM |
Theme |
Table5 Gastrointestinal disease area
Theme/Project |
Theme/Project Leader |
Modality |
Project (L3 to P3)/ Theme (S0 to L2) |
Antibody drug for hepatitis B |
CHAYAMA Kazuaki |
AB |
Theme |
Drug development for hepatitis B |
OGAWA Kenji |
SM |
Theme |
Table6
Immune / allergic disease area
Theme/Project |
Theme/Project Leader |
Modality |
Project (L3 to P3)/ Theme (S0 to L2) |
Drug for atopic dermatitis |
MIYAI Tomohiro |
SM |
Theme |
Table7 Other area
Theme/Project |
Theme/Project Leader |
Modality |
Project (L3 to P3)/ Theme (S0 to L2) |
Establishment of a heart-on-a-chip microdevice based on
human iPS Cells |
MASUMOTO Hidetoshi |
BT |
Theme |
Mitochondrial translation-monitoring drug screening platform for mitochondrial diseases |
IWASAKI Shintaro |
SM |
Theme |